Achieving glycemic control in patients with type 2 diabetes and renal impairment

Acta Diabetologica

Volumn 50, Issue 3, 2013, Pages 283-291

  Avogaro, Angelo ^a   Schernthaner, Guntram ^b  

^a UNIVERSITY OF PADOVA   (Italy)

^b Rudolfstiftung   (Austria)

Author keywords

Chronic kidney disease; Glycemic control; Oral anti diabetes drugs; Renal impairment; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; BIGUANIDE DERIVATIVE; CREATININE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; INSULIN; LINAGLIPTIN; LIRAGLUTIDE; METFORMIN; MIGLITOL; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PLACEBO; REPAGLINIDE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; TELMISARTAN; VALSARTAN; VILDAGLIPTIN;

ANGIONEUROTIC EDEMA; BODY WEIGHT; CREATININE CLEARANCE; DIABETIC NEPHROPATHY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; LACTIC ACIDOSIS; LIVER DISEASE; MACROALBUMINURIA; MICROALBUMINURIA; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; WEIGHT REDUCTION;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; HUMANS; HYPOGLYCEMIC AGENTS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84879206953     PISSN: 09405429     EISSN: 14325233     Source Type: Journal    
DOI: 10.1007/s00592-012-0442-x     Document Type: Review

References (71)

1. Bash LD, Selvin E, Steffes M, Coresh J, Astor BC (2008) Poor glycemic control in diabetes and the risk of incident chronic kidney disease even in the absence of albuminuria and retinopathy: Atherosclerosis Risk in Communities (ARIC) Study. Arch Intern Med 168:2440-2447
2. de Boer IH, Rue TC, Cleary PA, Lachin JM, Molitch ME, Steffes MW, Sun W, Zinman B, Brunzell JD, White NH, Danis RP, Davis MD, Hainsworth D, Hubbard LD, Nathan DM (2011) Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort. Arch Intern Med 171:412-420
3. Shurraw S, Hemmelgarn B, Lin M, Majumdar SR, Klarenbach S, Manns B, Bello A, James M, Turin TC, Tonelli M (2011) Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease: a population-based cohort study. Arch Intern Med 171:1920-1927
4. Narayan KM, Gregg EW, Engelgau MM, Moore B, Thompson TJ, Williamson DF, Vinicor F (2000) Translation research for chronic disease: the case of diabetes. Diabetes Care 23:1794-1798
5. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G (2003) National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 139:137-147
6. National Kidney Foundation (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39(2 suppl 1):S1-S266
7. National Institute for Health and Clinical Excellence (2012) Chronic kidney disease: national clinical guideline for early identification and management in adults in primary and secondary care. Clin Guidel 73. http://www.nice.org.uk/nicemedia/live/12069/42117/42117.pdf. Accessed 5 Mar 2012
8. Koro CE, Lee BH, Bowlin SJ (2009) Antidiabetic medication use and prevalence of chronic kidney disease among patients with type 2 diabetes mellitus in the United States. Clin Ther 31:2608-2617
9. Huang ES, Liu JY, Moffet HH, John PM, Karter AJ (2011) Glycemic control, complications, and death in older diabetic patients: the diabetes and aging study. Diabetes Care 34:1329-1336
10. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR (2003) Development and progression of nephropathy in type 2 diabetes: the United Kingdom prospective diabetes study (UKPDS 64). Kidney Int 63:225-232
11. Schneider CA, Ferrannini E, Defronzo R, Schernthaner G, Yates J, Erdmann E (2008) Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease. J Am Soc Nephrol 19:182-187
12. Fernandez-Real JM, Vendrell J, Garcia I, Ricart W, Valles M (2012) Structural damage in diabetic nephropathy is associated with TNF-alpha system activity. Acta Diabetol 49:301-305
13. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O (2003) Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348:383-393
14. Gaede P, Lund-Andersen H, Parving HH, Pedersen O (2008) Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358:580-591
15. Zoungas S, de Galan BE, Ninomiya T, Grobbee D, Hamet P, Heller S, MacMahon S, Marre M, Neal B, Patel A, Woodward M, Chalmers J, Cass A, Glasziou P, Harrap S, Lisheng L, Mancia G, Pillai A, Poulter N, Perkovic V, Travert F (2009) Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: new results from the ADVANCE trial. Diabetes Care 32:2068-2074
16. Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, Cuddihy R, Cushman WC, Genuth S, Grimm RH Jr, Hamilton BP, Hoogwerf B, Karl D, Katz L, Krikorian A, O'Connor P, Pop-Busui R, Schubart U, Simmons D, Taylor H, Thomas A, Weiss D, Hramiak I (2010) Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 376:419-430
17. Selvin E, Ning Y, Steffes MW, Bash LD, Klein R, Wong TY, Astor BC, Sharrett AR, Brancati FL, Coresh J (2011) Glycated hemoglobin and the risk of kidney disease and retinopathy in adults with and without diabetes. Diabetes 60:298-305
18. Nathan D, Buse J, Davidson M, Ferrannini E, Holman R, Sherwin R, Zinman B (2009) Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. Diabetologia 52:17-30
19. National Kidney Foundation (2012) KDOQI Clinical Practice Guidelines for Diabetes and CKD: 2012 update. Am J Kidney Dis 60:850-886
20. Woerle HJ, Meyer C, Popa EM, Cryer PE, Gerich JE (2003) Renal compensation for impaired hepatic glucose release during hypoglycemia in type 2 diabetes: further evidence for hepatorenal reciprocity. Diabetes 52:1386-1392
21. Haneda M, Morikawa A (2009) Which hypoglycaemic agents to use in type 2 diabetic subjects with CKD and how? Nephrol Dial Transplant 24:338-341
22. Jonsson A, Rydberg T, Sterner G, Melander A (1998) Pharmacokinetics of glibenclamide and its metabolites in diabetic patients with impaired renal function. Eur J Clin Pharmacol 53:429-435
23. Accord Healthcare (2012) Glimepiride 4 mg tablets: summary of product characteristics. http://www.medicines.org.uk/EMC/history/25845/SPC/ Glimepiride+4+mg+Tablets. Accessed 5 Mar 2012
24. Schumacher S, Abbasi I, Weise D, Hatorp V, Sattler K, Sieber J, Hasslacher C (2001) Single- and multiple-dose pharmacokinetics of repaglinide in patients with type 2 diabetes and renal impairment. Eur J Clin Pharmacol 57:147-152
25. Aurobindo (2012) Metformin 500 mg tablets: summary of product characteristics. http://www.medicines.org.uk/EMC/medicine/23244/SPC/ Metformin+500mg+tablets. Accessed 5 Mar 2012
26. National Institute for Health and Clinical Excellence (2009) The management of type 2 diabetes. Clin Guidel 87. http://www.nice.org.uk/nicemedia/ live/12165/44320/44320.pdf. Accessed 5 Mar 2012
27. Rodbard HW, Blonde L, Braithwaite SS, Brett EM, Cobin RH, Handelsman Y, Hellman R, Jellinger PS, Jovanovic LG, Levy P, Mechanick JI, Zangeneh F (2007) American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 13(Suppl 1):1-68
28. Diabetes Australia Guideline Development Consortium (2009) National evidence-based guideline for blood glucose control in type 2 diabetes. http://www.nhmrc.gov.au/-files-nhmrc/publications/attachments/ di19-diabetes-blood-glucose-control.pdf. Accessed 5 Mar 2012
29. Canadian Diabetes Association (2008) Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 32(suppl 1):S1-S201
30. Schernthaner G, Ritz E, Schernthaner GH (2010) Strict glycaemic control in diabetic patients with CKD or ESRD: beneficial or deadly? Nephrol Dial Transplant 25:2044-2047
31. Sanofi (2012) Insuman basal (100 IU/ml): summary of product characteristics. http://www.medicines.org.uk/EMC/medicine/3559/SPC/ Insuman+Basal+(100+IU+ml). Accessed 1 Oct 2012
32. Novo Nordisk (2012) Victoza 6 mg/ml solution for injection in pre-filled pen: summary of product characteristics. http://www.medicines.org.uk/EMC/ medicine/21986/SPC/Victoza+6+mg+ml+solution+for+injection+in+pre-filled+pen/. Accessed 1 Oct 2012
33. Eli Lilly (2011) Bydureon 2 mg powder and solvent for prolonged-release suspension for injection: summary of product characteristics. http://www.medicines.org.uk/EMC/medicine/24665/SPC/ BYDUREON+2+mg+powder+and+solvent+for+prolonged-release+suspension+for+injection/ . Accessed 1 Oct 2012
34. Boehringer Ingelheim (2011) Trajenta 5 mg film-coated tablets: summary of product characteristics. http://www.medicines.org.uk/EMC/medicine/25000/SPC/ Trajenta+5+mg+film-coated+tablets/. Accessed 1 Oct 2012
35. Bristol-Myers Squibb, AstraZeneca (2012) Onglyza 2.5 mg and 5 mg film-coated tablets: summary of product characteristics. http://www.medicines. org.uk/EMC/medicine/22315/SPC/Onglyza+2.5mg+%26+5mg+film-coated+tablets/. Accessed 1 Oct 2012
36. Merck Sharp & Dohme (2012) Januvia 25 mg, 50 mg, 100 mg film-coated tablets: summary of product characteristics. http://www.medicines.org.uk/EMC/ medicine/19609/SPC/JANUVIA+25mg%2c+50mg%2c+100mg+film-coated+tablets/. Accessed 2 Oct 2012
37. Novartis (2012) Galvus 50 mg tablets: summary of product characteristics. http://www.medicines.org.uk/emc/medicine/20734. Accessed 1 Oct 2012
38. Consilient Health (2012) Pioglitazone 15 mg tablets: summary of product characteristics. http://www.medicines.org.uk/EMC/medicine/24919/SPC/ Pioglitazone+15+mg+tablets/. Accessed 5 Mar 2012
39. Bayer (2012) Glucobay 100 mg tablets: summary of product characteristics. http://www.medicines.org.uk/EMC/medicine/19973/SPC/Glucobay+100+mg+tablets/. Accessed 2 Oct 2012
40. Pharmacia and Upjohn (2010) Glyset (miglitol) tablet, film coated: human prescription drug label. http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid= 75711d16-2d27-476e-a312-d5af448a0e25. Accessed 5 Mar 2012
41. Actavis (2012) Repaglinide 0.5 mg tablets: summary of product characteristics. http://www.medicines.org.uk/EMC/medicine/24635/SPC/ Repaglinide+0.5+mg+Tablets/. Accessed 5 Mar 2012
42. Aurobindo (2010) Gliclazide 80 mg tablets: summary of product characteristics. http://www.medicines.org.uk/EMC/medicine/23094/SPC/ Gliclazide+80mg+Tablets/. Accessed 5 Mar 2012
43. Lipska KJ, Bailey CJ, Inzucchi SE (2011) Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care 34:1431-1437
44. Keane WF, Brenner BM, de Zeeuw D, Grunfeld JP, McGill J, Mitch WE, Ribeiro AB, Shahinfar S, Simpson RL, Snapinn SM, Toto R (2003) The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int 63:1499-1507
45. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R (2009) A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361:2019-2032
46. Galle J, Schwedhelm E, Pinnetti S, Boger RH, Wanner C (2008) Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy. Nephrol Dial Transplant 23:3174-3183
47. Joss N, Ferguson C, Brown C, Deighan CJ, Paterson KR, Boulton-Jones JM (2004) Intensified treatment of patients with type 2 diabetes mellitus and overt nephropathy. QJM 97:219-227
48. Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, Drury PL, Esmatjes E, Hricik D, Parikh CR, Raz I, Vanhille P, Wiegmann TB, Wolfe BM, Locatelli F, Goldhaber SZ, Lewis EJ (2003) Cardiovascular outcomes in the irbesartan diabetic nephropathy trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med 138:542-549
49. Roussel R, Travert F, Pasquet B, Wilson PW, Smith SC Jr, Goto S, Ravaud P, Marre M, Porath A, Bhatt DL, Steg PG (2010) Metformin use and mortality among patients with diabetes and atherothrombosis. Arch Intern Med 170:1892-1899
50. Pharmacia (2010) Minodiab 5 mg tablets: summary of product characteristics. http://www.medicines.org.uk/emc/medicine/9851/SPC/. Accessed 5 Mar 2012
51. Malaisse WJ (2006) Gliquidone contributes to improvement of type 2 diabetes mellitus management: a review of pharmacokinetic and clinical trial data. Drugs R D 7:331-337
52. Scheen AJ (2007) Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide. Clin Pharmacokinet 46:93-108
53. Biesenbach G, Raml A, Schmekal B, Eichbauer-Sturm G (2003) Decreased insulin requirement in relation to GFR in nephropathic Type 1 and insulin-treated Type 2 diabetic patients. Diabet Med 20:642-645
54. Kendall DM, Cuddihy RM, Bergenstal RM (2009) Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use. Am J Med 122:S37-S50
55. Copley K, McCowen K, Hiles R, Nielsen LL, Young A, Parkes DG (2006) Investigation of exenatide elimination and its in vivo and in vitro degradation. Curr Drug Metab 7:367-374
56. Linnebjerg H, Kothare PA, Park S, Mace K, Reddy S, Mitchell M, Lins R (2007) Effect of renal impairment on the pharmacokinetics of exenatide. Br J Clin Pharmacol 64:317-327
57. Ferrer-Garcia JC, Martinez-Chanza N, Tolosa-Torrens M, Sanchez-Juan C (2010) Exenatide and renal failure. Diabet Med 27:728-729
58. Johansen OE, Whitfield R (2008) Exenatide may aggravate moderate diabetic renal impairment: a case report. Br J Clin Pharmacol 66:568-569
59. Weise WJ, Sivanandy MS, Block CA, Comi RJ (2009) Exenatide-associated ischemic renal failure. Diabetes Care 32:e22-e23
60. Jacobsen LV, Hindsberger C, Robson R, Zdravkovic M (2009) Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide. Br J Clin Pharmacol 68:898-905
61. Davidson JA, Brett J, Falahati A, Scott D (2010) Mild renal impairment has no effect on the efficacy and safety of liraglutide. Endocr Pract 6:1-31
62. Lukashevich V, Schweizer A, Shao Q, Groop PH, Kothny W (2011) Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial. Diabetes Obes Metab 13:947-954
63. Chan JC, Scott R, Arjona Ferreira JC, Sheng D, Gonzalez E, Davies MJ, Stein PP, Kaufman KD, Amatruda JM, Williams-Herman D (2008) Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes Metab 10:545-555
64. Bergman AJ, Cote J, Yi B, Marbury T, Swan SK, Smith W, Gottesdiener K, Wagner J, Herman GA (2007) Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Diabetes Care 30:1862-1864
65. Graefe-Mody U, Friedrich C, Port A, Ring A, Retlich S, Heise T, Halabi A, Woerle HJ (2011) Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin. Diabetes Obes Metab 13:939-946
66. Nowicki M, Rychlik I, Haller H, Warren ML, Suchower L, Gause-Nilsson I (2011) Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment. Diabetes Obes Metab 13:523-532
67. FDA updated guidance on saxagliptin (2011). http://www.accessdata.fda. gov/drugsatfda-docs/label/2011/022350s004lbl.pdf. Accessed 1 Oct 2012
68. Drucker DJ (2007) Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action. Diabetes Care 30:1335-1343
69. Brown NJ, Byiers S, Carr D, Maldonado M, Warner BA (2009) Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema. Hypertension 54:516-523
70. Marney A, Kunchakarra S, Byrne L, Brown NJ (2010) Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans. Hypertension 56:728-733
71. Atkins RC, Zimmet P (2010) Diabetic kidney disease: act now or pay later. Acta Diabetol 47:1-4